150 related articles for article (PubMed ID: 35700815)
21. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
Jones NA; Hill AJ; Smith I; Bevan SA; Williams CM; Whalley BJ; Stephens GJ
J Pharmacol Exp Ther; 2010 Feb; 332(2):569-77. PubMed ID: 19906779
[TBL] [Abstract][Full Text] [Related]
22. Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model.
Khan AA; Shekh-Ahmad T; Khalil A; Walker MC; Ali AB
Br J Pharmacol; 2018 Jun; 175(11):2097-2115. PubMed ID: 29574880
[TBL] [Abstract][Full Text] [Related]
23. Anticonvulsant and Neuroprotective Effects of Cannabidiol During the Juvenile Period.
Friedman LK; Wongvravit JP
J Neuropathol Exp Neurol; 2018 Oct; 77(10):904-919. PubMed ID: 30169677
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam.
Rana RR; Rajasekaran K; Knappertz V; Gray RA
Exp Neurol; 2023 Feb; 360():114286. PubMed ID: 36442674
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol in the Treatment of Epilepsy.
von Wrede R; Helmstaedter C; Surges R
Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
[TBL] [Abstract][Full Text] [Related]
26. Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se.
Hill AJ; Jones NA; Smith I; Hill CL; Williams CM; Stephens GJ; Whalley BJ
Neurosci Lett; 2014 Apr; 566():269-74. PubMed ID: 24642454
[TBL] [Abstract][Full Text] [Related]
27. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
28. Roles of astrocytes and microglia in seizure-induced aberrant neurogenesis in the hippocampus of adult rats.
Yang F; Liu ZR; Chen J; Zhang SJ; Quan QY; Huang YG; Jiang W
J Neurosci Res; 2010 Feb; 88(3):519-29. PubMed ID: 19774666
[TBL] [Abstract][Full Text] [Related]
29. Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy.
Strickland JC; Jackson H; Schlienz NJ; Salpekar JA; Martin EL; Munson J; Bonn-Miller MO; Vandrey R
Epilepsy Behav; 2021 Sep; 122():108205. PubMed ID: 34311183
[TBL] [Abstract][Full Text] [Related]
30. Effects of Epidiolex® (Cannabidiol) on seizure-related emergency department visits and hospital admissions: A retrospective cohort study.
Abu-Sawwa R; Chase A; Fowowe O; Park Y
Epilepsy Behav; 2022 Feb; 127():108538. PubMed ID: 35051868
[TBL] [Abstract][Full Text] [Related]
31. The Potential Mechanism of Cannabidiol (CBD) Treatment of Epilepsy in Pentetrazol (PTZ) Kindling Mice Uncovered by Multi-Omics Analysis.
Lu H; Wang Q; Jiang X; Zhao Y; He M; Wei M
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985783
[TBL] [Abstract][Full Text] [Related]
32. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
[TBL] [Abstract][Full Text] [Related]
33. Preclinical efficacy of cannabidiol for the treatment of early-life seizures.
Witherspoon E; Quinlan S; Forcelli PA
Pharmacol Rep; 2022 Oct; 74(5):1092-1098. PubMed ID: 36220975
[TBL] [Abstract][Full Text] [Related]
34. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.
McGrath S; Bartner LR; Rao S; Packer RA; Gustafson DL
J Am Vet Med Assoc; 2019 Jun; 254(11):1301-1308. PubMed ID: 31067185
[TBL] [Abstract][Full Text] [Related]
35. Cannabidiol in treatment of refractory epileptic spasms: An open-label study.
Herlopian A; Hess EJ; Barnett J; Geffrey AL; Pollack SF; Skirvin L; Bruno P; Sourbron J; Thiele EA
Epilepsy Behav; 2020 May; 106():106988. PubMed ID: 32169600
[TBL] [Abstract][Full Text] [Related]
36. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
[TBL] [Abstract][Full Text] [Related]
38. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.
Martín-Moreno AM; Reigada D; Ramírez BG; Mechoulam R; Innamorato N; Cuadrado A; de Ceballos ML
Mol Pharmacol; 2011 Jun; 79(6):964-73. PubMed ID: 21350020
[TBL] [Abstract][Full Text] [Related]
39. Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels.
Vilela LR; Lima IV; Kunsch ÉB; Pinto HPP; de Miranda AS; Vieira ÉLM; de Oliveira ACP; Moraes MFD; Teixeira AL; Moreira FA
Epilepsy Behav; 2017 Oct; 75():29-35. PubMed ID: 28821005
[TBL] [Abstract][Full Text] [Related]
40. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
Campos AC; Ortega Z; Palazuelos J; Fogaça MV; Aguiar DC; Díaz-Alonso J; Ortega-Gutiérrez S; Vázquez-Villa H; Moreira FA; Guzmán M; Galve-Roperh I; Guimarães FS
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1407-19. PubMed ID: 23298518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
